MedDataX Logo

An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

NCT ID: NCT00111891

Last Updated: 2017-02-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

575 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-06-30

Study Completion Date

2005-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)

NCT00378833

Hypercholesterolemia Hyperlipidemia
COMPLETED PHASE3

Lipid Efficacy/Tolerability Study (0524A-020)

NCT00269204

Primary Hypercholesterolaemia Mixed Hyperlipidaemia
COMPLETED PHASE3

MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

NCT00533312

Hypercholesterolemia
COMPLETED PHASE2

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

NCT00664287

Dyslipidemia
WITHDRAWN PHASE3

MK0524A Phase IIb Study (0524A-011)(COMPLETED)

NCT00536237

Flushing
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The duration of treatment is 7 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

niacin (+) laropiprant

Intervention Type DRUG

Comparator: placebo (unspecified)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK0524A

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females (ages 25-75)

Exclusion Criteria

* A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study
Minimum Eligible Age

25 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Monitor

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: CSR Synopsis

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MK0524A-032

Identifier Type: -

Identifier Source: secondary_id

2005_032

Identifier Type: -

Identifier Source: secondary_id

0524-032

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158)
NCT01583647 TERMINATED PHASE1
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
NCT00376584 COMPLETED PHASE3
MK0524A Bioequivalence Study (0524A-059)
NCT00944645 COMPLETED PHASE1
A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)
NCT00961636 COMPLETED PHASE3
A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood
NCT05979428 COMPLETED PHASE1
Effect of MK0524A on Cholesterol Levels (0524A-048)
NCT00536510 COMPLETED PHASE3
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
NCT00079638 COMPLETED PHASE4
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
NCT00769132 COMPLETED PHASE1
Effect of Niacin on Transport of HDL and Relationship to Atherogenic Lipoproteins and Lipolysis
NCT01250990 COMPLETED NA
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
NCT00304993 COMPLETED PHASE4
Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia
NCT01239992 TERMINATED PHASE4
Effects of Niacin On Fatty Acid Trapping
NCT01984073 COMPLETED PHASE1
Study to Test GSK256073 in Patients With Dyslipidemia
NCT00903617 COMPLETED PHASE2
Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic
NCT06109831 COMPLETED PHASE2
Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST
NCT00082251 COMPLETED PHASE3
Study of MB07811 in Subjects With Hypercholesterolemia
NCT00879112 WITHDRAWN PHASE2
Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects
NCT02676596 COMPLETED PHASE1
An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism
NCT00847782 COMPLETED NA
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE
NCT00461630 COMPLETED PHASE3
Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease
NCT01308203 TERMINATED PHASE4
Effects of Psyllium on Niacin Tolerability
NCT03370848 COMPLETED PHASE4
A Phase II Study To Evaluate the Efficacy And Safety Of HRS-1301 In Participants With Dyslipidemia
NCT07229937 RECRUITING PHASE2
Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females
NCT03615534 COMPLETED PHASE4
Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)
NCT01071291 COMPLETED PHASE1
Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome
NCT01118598 COMPLETED PHASE4